Parkinson’s disease and nutrition: what the evidence shows and what matters in practice

Richard Moore
Mar 27
13 min read

Parkinson’s disease is often introduced through the symptoms people can see most clearly: tremor, stiffness, slowness of movement and balance difficulty (NINDS, 2024). Yet for many people living with Parkinson’s, and for the families and carers supporting them, the condition is shaped just as much by what happens beyond movement: constipation, loss of smell, sleep disturbance, difficulty maintaining blood pressure on standing, reduced appetite, swallowing problems and unplanned weight change (NINDS, 2024; Gabriel et al., 2026). That wider picture matters because it is often where nutrition becomes clinically relevant.

Nutrition is not a cure for Parkinson’s disease, and no single diet has been shown to stop or reverse its progression (Wu et al., 2024). But that should not be mistaken for a minor role. Nutrition sits at the centre of several practical issues that affect day-to-day function and quality of life, including bowel regularity, medication response, muscle and bone health, micronutrient status, frailty risk and body weight stability (Gabriel et al., 2026; Shuler et al., 2026). In Parkinson’s care, these are not background details. They are often part of the main clinical work.

What Parkinson’s disease actually is, and why the gut keeps entering the story

Parkinson’s disease is a progressive neurodegenerative condition in which dopamine-producing nerve cells, particularly in the substantia nigra, are gradually lost (NINDS, 2024). Dopamine helps the brain regulate smooth, coordinated movement, so when dopamine signalling falls, movement becomes slower, stiffer and less fluid (NINDS, 2024). Parkinson’s also affects more than dopamine systems alone, which helps explain why non-motor symptoms can be so prominent and why changes in digestion, smell, sleep and autonomic function can appear long before, or alongside, the better-known motor signs (NINDS, 2024).

One helpful way to think about Parkinson’s is that it can disturb timing across several systems at once. The brain, gut, muscles and automatic body functions, such as bowel movement and blood pressure regulation, begin to lose some of their usual coordination (NINDS, 2024; Warnecke et al., 2022). That helps explain why constipation, delayed stomach emptying, feeling full quickly and swallowing difficulties are so common, and why these are not incidental add-ons to a movement disorder but part of the wider physiology of the disease (Warnecke et al., 2022; Gabriel et al., 2026).

The diet question most people ask, and the more careful answer the evidence gives

When people ask for the best diet for Parkinson’s disease, they usually want a simple winner. The literature is not quite that tidy. Even so, if one broad pattern currently has the strongest practical case behind it, it is a Mediterranean-style pattern built around vegetables, fruit, legumes, whole grains, nuts, olive oil, herbs and regular fish, with less emphasis on highly processed foods and processed meats (Rusch et al., 2024; Rees et al., 2024; Shuler et al., 2026). That is not because it has been shown to halt Parkinson’s progression. It is because it combines nutrient density, fibre, a plausible anti-inflammatory profile and broader cardiometabolic benefits with some early Parkinson’s-specific trial data.

Part of its appeal is very practical. Mediterranean-style eating usually raises fibre intake, and constipation is one of the commonest and most burdensome non-motor symptoms in Parkinson’s disease (Warnecke et al., 2022; Shuler et al., 2026). It also tends to increase intake of polyphenol-rich foods, such as berries, olives, herbs, tea and cocoa, which are being studied because they may influence oxidative stress, inflammation and the gut microbiome (Chen et al., 2025). That does not make them proven disease-modifying treatments, but it does help explain why plant-rich dietary patterns keep resurfacing in Parkinson’s nutrition research (Chen et al., 2025).

The supportive literature still needs to be read with care. Much of the earlier enthusiasm around Mediterranean-style eating came from observational studies, and observational studies cannot fully separate diet from the other behaviours that often travel with it, such as higher physical activity, lower smoking rates or stronger healthcare engagement (Rees et al., 2024; Zhao et al., 2024). So when stronger Mediterranean-diet adherence is associated with lower Parkinson’s risk or later onset, that is encouraging, but it is not the same as proof of causation (Zhao et al., 2024).

The more useful clinical evidence comes from intervention trials. In a 2024 randomized controlled trial, people with Parkinson’s disease and constipation who were supported to follow a Mediterranean diet showed greater improvement in constipation symptoms and lower faecal calprotectin than the control group at eight weeks, suggesting an effect on gut-related symptom burden and intestinal inflammation markers (Rusch et al., 2024). That matters because constipation is not a small side issue in Parkinson’s. It can affect comfort, appetite and the rhythm of the day, and may also influence how medication feels from one meal to the next (Rusch et al., 2024; Warnecke et al., 2022). But this was still a relatively small, short-term study focused mainly on gastrointestinal outcomes rather than long-term disease progression (Rusch et al., 2024). So the fairest conclusion is that Mediterranean-style eating is the strongest broad framework we currently have, especially for bowel support and general health, while direct disease-modifying effects remain unproven.

The issue that can matter more than the menu itself: protein and levodopa

For many people with Parkinson’s, levodopa, one of the main medicines used to improve movement symptoms, is central to daily life (Shuler et al., 2026). What many people do not hear early enough is that dietary protein can sometimes interfere with how levodopa works. Amino acids, the building blocks of protein, can compete with levodopa for transport across the small intestine and at the blood-brain barrier, which means a protein-rich meal can sometimes make medication response feel less predictable (Shuler et al., 2026).

This is why protein redistribution diets have remained relevant in Parkinson’s care. The idea is not severe protein restriction, but shifting a larger share of protein into the evening so daytime levodopa has less competition when mobility is most needed (Shuler et al., 2026). The 2026 Practical Neurology review reports that 14 trials have examined protein redistribution in Parkinson’s disease and that, overall, these diets have prolonged “on” periods, meaning times when medication is working well, and improved motor function (Shuler et al., 2026). That review is particularly useful here because it brings together a scattered trial literature in a clinically practical way.

Even here, caution matters. Protein redistribution can become counterproductive if total protein intake falls too low, energy intake drops, or body weight begins to slip in someone already vulnerable to malnutrition or loss of muscle mass and strength, often called sarcopenia (Shuler et al., 2026). The review also notes that most of the trials were small, many were non-randomized, and only four were randomized controlled trials (Shuler et al., 2026). So this is best viewed as a targeted clinical strategy for selected patients with motor fluctuations, not a universal rule for everyone with Parkinson’s.

Ketogenic diets: scientifically interesting, but not the leading clinical answer

Ketogenic diets keep attracting attention in neurological disease because they shift fuel use, increase ketone production and may influence mitochondrial function and cellular stress signalling (Shuler et al., 2026). That makes them scientifically interesting in Parkinson’s disease, and a handful of pilot studies have tested whether they might improve symptoms in selected patients (Phillips et al., 2018; Krikorian et al., 2019; Choi et al., 2024).

At the moment, though, the evidence is still too limited and too inconsistent to place ketogenic strategies ahead of more practical and better-supported approaches. The review also notes that only four randomised trials were available, several were pilot or feasibility studies, and results did not show a consistent improvement in overall Parkinson’s symptom severity or progression (Shuler et al., 2026). Some studies also reported concerns such as worsening tremor or involuntary movements in some participants, increased LDL cholesterol and clinically relevant weight loss (Shuler et al., 2026). In a population already vulnerable to weight loss and malnutrition, that matters a great deal (Gabriel et al., 2026).

Nutrients worth watching closely, and why correction matters more than excess

One of the steadier messages in this field is that monitoring and correcting deficiency is usually more defensible than recommending long lists of supplements by default (Shuler et al., 2026). That may sound less exciting than a more aggressive protocol, but it is much closer to what the evidence supports.

Vitamin D is a good example. Lower vitamin D status and lower bone mineral density are both common concerns in Parkinson’s disease, which matters in a group already at increased risk of falls and fractures (Shuler et al., 2026). A 2025 meta-analysis of randomised controlled trials found that vitamin D supplementation did not significantly improve several key motor outcomes, although it may improve six-minute walk distance and some partial motor measures (Xu et al., 2025). So vitamin D still matters, especially for bone and musculoskeletal health, but it should not be presented as a proven treatment for the core motor features of Parkinson’s disease.

Folate and vitamin B12 also deserve attention. The Practical Neurology review notes that reduced serum concentrations of vitamins B9 and B12 can occur in Parkinson’s disease and that levodopa-treated patients may develop raised homocysteine alongside lower B9 and B12 status (Shuler et al., 2026). In practice, that supports targeted monitoring and correction where needed, rather than blanket high-dose supplementation for everyone.

Supplements: a few useful niches, many unanswered questions

If the supplement literature in Parkinson’s disease teaches one thing, it is that a plausible mechanism is not the same as a reliable clinical effect. A 2024 meta-analysis of randomised and crossover studies found some metabolic effects from dietary supplements, foods and dietary patterns, but no clear overall benefit across the supplement literature for key Parkinson’s rating-scale outcomes or six-minute walk distance (Wu et al., 2024). In other words, there are signals, but not many firm conclusions.

There are, however, narrower areas where supplementation may help. Probiotics and synbiotics are one example. Three meta-analyses summarised in the Practical Neurology review show that probiotic and/or synbiotic supplementation significantly increased bowel movement frequency, and one review also found improved stool consistency and reduced laxative use (Shuler et al., 2026). That aligns with the earlier randomised trial by Barichella and colleagues, which found that a fermented milk containing probiotics and prebiotic fibre improved complete bowel movements in people with Parkinson’s disease and constipation (Barichella et al., 2016). That does not mean probiotics treat Parkinson’s disease broadly. But it does suggest they may help with one symptom that meaningfully affects comfort and day-to-day function.

Omega-3 fatty acids, especially when combined with vitamin E, are another area of interest. Earlier randomised work suggested possible improvements in Parkinson’s rating-scale scores and some inflammatory or antioxidant markers after 12 weeks of co-supplementation (Taghizadeh et al., 2017). But the overall evidence base remains small, which makes omega-3s worth watching rather than settled as a Parkinson’s-specific intervention.

Coenzyme Q10 is a useful reminder that biologically elegant ideas do not always translate into clinical benefit. Despite earlier interest driven by mitochondrial theory, larger clinical testing did not show benefit in early Parkinson’s disease, and major professional bodies do not regard it as efficacious for preventing or delaying progression (Beal et al., 2014; Shuler et al., 2026).

Lifestyle still matters, perhaps more than many people expect

Nutrition does not act alone. Exercise remains one of the strongest non-drug interventions in Parkinson’s care. A large Cochrane network meta-analysis found that many forms of physical exercise improve the severity of motor signs and quality of life in Parkinson’s disease, with little evidence that one single type is consistently best for everyone (Ernst et al., 2023). That is actually helpful, because it shifts the emphasis away from finding the perfect exercise and toward finding movement that is safe, progressive and sustainable enough to keep doing.

This matters because Parkinson’s can behave like a condition in which inactivity compounds loss. Reduced movement can worsen stiffness and deconditioning, which can then further narrow confidence, function and independence (Ernst et al., 2023). In practice, some of the most valuable care is the least dramatic: regular movement, good hydration, bowel support, swallowing assessment when needed, appropriate meal structure and early nutrition input before someone becomes visibly frail.

When the scale starts to fall: why weight maintenance deserves far more attention

If one nutritional issue in Parkinson’s disease is consistently underestimated, it is weight loss. The 2026 review by Gabriel and colleagues describes progressive weight decline as a consistent and concerning trend in Parkinson’s disease, with many patients losing substantially more weight than age- and sex-matched controls over time (Gabriel et al., 2026). Weight loss may begin years before formal diagnosis, can accelerate later in the disease course, and is associated with more advanced disease, frailty, poorer quality of life and worse overall prognosis (Gabriel et al., 2026).

The causes are rarely simple. Weight loss in Parkinson’s can reflect reduced food intake, swallowing difficulty, constipation, delayed stomach emptying, altered energy expenditure, dyskinesia, cognitive decline, smell changes, medication effects and broader metabolic or neuroendocrine shifts, often in overlapping combinations rather than tidy categories (Gabriel et al., 2026). That is why weight loss in Parkinson’s is often better understood as a clinical warning sign than as a minor side effect. It often means several systems are straining at once.

The same review states that weight loss greater than 5% over 3 months or greater than 10% over 6 months is clinically relevant and indicates a higher risk of malnutrition, with further assessment recommended in those cases (Gabriel et al., 2026). It also argues that discussions about nutritional intervention should begin early, when people are still cognitively and physically able to take part fully in decisions, and notes that improvement in nutritional status correlates with improvement in quality of life (Gabriel et al., 2026). In practical terms, protecting weight may mean smaller, more frequent meals, energy-dense nourishing foods, early management of constipation and early satiety, swallowing support where needed, and ensuring that strategies to improve levodopa response do not quietly reduce total energy or protein intake too far. In Parkinson’s disease, maintaining body weight is not separate from maintaining function. It is part of the same job.

Research opening new doors, and why it still needs patience

Some of the most interesting recent Parkinson’s research sits at the edge of metabolism and neurodegeneration. In a 2024 phase 2 trial, lixisenatide, a GLP-1 receptor agonist, resulted in less progression of motor disability than placebo over 12 months in people with early Parkinson’s disease, although gastrointestinal side effects were common and longer, larger trials were needed (Meissner et al., 2024). That was an important result because it suggested that metabolic pathways may matter to disease course, not only symptom management.

At the same time, a 2025 phase 3 trial of exenatide, another GLP-1 receptor agonist, found no evidence that it slowed Parkinson’s progression (Vijiaratnam et al., 2025). That contrast is a useful reminder of how this field moves. An early positive study can open a promising line of enquiry, but it does not settle the question. The research is moving, but it is still moving carefully.

What this means in practice

Taken together, the evidence points less toward a single “Parkinson’s diet” and more toward an individualised approach built on a sensible foundation. For many people, that foundation will look Mediterranean-style, fibre-rich and minimally processed, because it supports bowel health, nutrient density and broader metabolic resilience (Rusch et al., 2024; Rees et al., 2024). From there, the plan often needs tailoring around the issues that actually drive daily difficulty: levodopa timing, constipation, low appetite, swallowing changes, vitamin status and the prevention of gradual weight loss (Gabriel et al., 2026; Shuler et al., 2026).

That may sound less dramatic than the search for one breakthrough food or supplement. But in practice, preserving bowel function, medication response, muscle mass, bone health and body weight can make a meaningful difference to comfort, confidence and independence. In Parkinson’s care, that is often where good nutrition does its best work.

How You Nutrition Clinic can help

At You Nutrition, we understand that Parkinson’s support needs to go beyond generic healthy-eating advice. The condition can affect movement, digestion, medication response, appetite, weight, energy, bowel function and confidence around food, often all at once. That calls for a plan that is evidence-based, clinically thoughtful and realistic enough to work in day-to-day life.

Our Parkinon's specialist RNTP Melody brings a focused neuro-nutrition lens to this work. Her approach integrates the latest research in neuroinflammation, mitochondrial function, oxidative stress and microbiome diversity to create tailored strategies that support both motor and non-motor symptoms. That may include support around constipation, meal timing with levodopa, maintaining body weight, improving meal structure, addressing nutritional insufficiencies and helping patients and carers make sense of a complex evidence base. The wider You Nutrition teaching material also emphasises an evidence-based approach that fits the person’s symptoms, preferences, capability and capacity, using a slow, steady and supportive model rather than a generic template.

If you would like support for yourself, a family member or a patient, You Nutrition offers personalised guidance designed to meet people where they are. For a free chat to see how we can help, please email admin@yountritionclinic.com.

We are also developing Parkinson’s Practitioner Training. To register your interest in this, email info@younutritionclinic.com.

References

Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., Caccialanza, R., Pezzoli, G., & Cereda, E. (2016). Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology, 87(12), 1274-1280.

Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., Ravina, B., Shults, C. M., Helles, K., Snively, V., Lew, M. F., Griebner, B., Watts, A., Gao, S., Pourcher, E., Bond, L., … Parkinson Study Group QE3 Investigators. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurology, 71(5), 543-552.

Chen, W., Fan, T., & Xu, R. (2025). Diet for the prevention and treatment of Parkinson's disease. Frontiers in Nutrition, 12, 1587246.

Ernst, M., Folkerts, A.-K., Gollan, R., Heuß, D., Krismer, F., Krüger, R., Mehanna, R., Schmitz-Hübsch, T., Elble, R., & Storch, A. (2023). Physical exercise for people with Parkinson's disease. Cochrane Database of Systematic Reviews, 1, CD013856.

Gabriel, E. D., Eisinger, R. S., Lee, J. M., Hamimi, S., Kim, H., Howard, S. D., & Halpern, C. H. (2026). When the scale drops: Pathways to weight loss in Parkinson's disease and future directions. Movement Disorders.

Meissner, W. G., Imbert, G., Debs, R., Tison, F., Rascol, O., Witjas, T., Azulay, J.-P., Spielmanns, M., Gandon, J.-M., Remen, A., et al. (2024). Trial of lixisenatide in early Parkinson's disease. New England Journal of Medicine, 390(13), 1176-1185.

National Institute of Neurological Disorders and Stroke. (2024). Parkinson's disease awareness month 2024: Accelerating progress and narrowing gaps.

Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018). Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial. Movement Disorders, 33(8), 1306-1314.

Rees, J., Ryan, J., Laws, M., et al. (2024). A comprehensive examination of the evidence for whole of diet patterns in Parkinson's disease: A scoping review. Nutritional Neuroscience, 27(6), 547-565.

Rusch, C., Chen, K.-Y., Ohlson, C. E., Campbell, K., Lim, E., Raza, S., Mai, V., Stiep, T., Ramirez-Zamora, A., Hess, C. W., & Langkamp-Henken, B. (2024). Promotion of a Mediterranean diet alters constipation symptoms and fecal calprotectin in people with Parkinson's disease: A randomized controlled trial. Nutrients, 16(17), 2946.

Shuler, M. S., Prasad, A., Flanagan, R., Dayal, V., & Lithander, F. E. (2026). Nutrition in Parkinson's disease: What neurologists need to know. Practical Neurology.

Taghizadeh, M., Tamtaji, O. R., Dadgostar, E., Daneshvar Kakhaki, R., Bahmani, F., Abolhassani, J., & Asemi, Z. (2017). The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical signs and metabolic status in patients with Parkinson's disease. International Journal for Vitamin and Nutrition Research, 87(1-2), 1-9.

Vijiaratnam, N., Athauda, D., Maclagan, K., et al. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet, 405, 709-720.

Warnecke, T., Schäfer, K.-H., & Claus, I. (2022). Gastrointestinal involvement in Parkinson's disease: Pathophysiology, diagnosis, and management. npj Parkinson's Disease, 8, 31.

Wu, L., Chu, L., Pang, Y., Huo, J., Cao, H., Tian, Q., & Gao, Q. (2024). Effects of dietary supplements, foods, and dietary patterns in Parkinson's disease: Meta-analysis and systematic review of randomized and crossover studies. European Journal of Clinical Nutrition, 78(5), 365-375.

Xu, J., Li, J., Sun, X., Quan, X., Qin, X., Song, Y., & Chen, J. (2025). Effect of vitamin D supplementation on motor symptoms in Parkinson's disease: A meta-analysis of randomized controlled trials. Frontiers in Nutrition, 12, 1500875.

Zhao, J., Peng, Y., Lin, Z., & Gong, Y. (2024). Association between Mediterranean diet adherence and Parkinson's disease: A systematic review and meta-analysis. The Journal of Nutrition, Health & Aging, 29, 100451.